The "Ocular Melanoma - Epidemiology Forecast - 2034" report has been added to ResearchAndMarkets.com's offering.The report delivers an in-depth understanding of ocular melanoma, historical and ...
The "Myopic Macular Degeneration (MMD) - Epidemiology Forecast - 2034" report has been added to ResearchAndMarkets.com's offering.The report delivers an in-depth understanding of Myopic Macular ...
PRISM evaluates 4D-150, a potential backbone therapy designed to provide multi-year sustained delivery of anti-VEGF ...
Stock analysts at Leerink Partnrs upped their Q1 2025 earnings per share (EPS) estimates for Regeneron Pharmaceuticals in a ...
D Molecular Therapeutics reported 52-week Phase 2b data for 4D-150 in wet AMD, showing sustained visual acuity improvements.
Guanfacine used for treating ADHD in children and adolescents increases corneal aberrations at 6 months but does not affect the retina, choroid, refraction, or optic nerve.
This research team evaluated the effectiveness of switching patients to faricimab treatment by assessing their outcomes after ...
Leerink Partners upgraded shares of Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) from a market perform rating to an ...
Atropine therapy has a direct treatment effect on choroidal thickness, which cannot be fully explained by axial length or SER changes.
CHMP Adopts Positive Opinion for Aflibercept, Pegfilgrastim Biosimilars: On January 30, 2025, the European Medicines Agency (EMA) Committee ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback